Clinical Trials Logo

Recurrent Lung Carcinoma clinical trials

View clinical trials related to Recurrent Lung Carcinoma.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04267913 Withdrawn - Clinical trials for Stage IV Lung Cancer AJCC v8

Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)

Start date: September 5, 2020
Phase: Phase 2
Study type: Interventional

This phase II LUNG-MAP treatment trial studies how well sapanisertib and docetaxel work for the treatment for squamous cell lung cancer that is stage IV or has come back (recurrent). Sapanisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving sapanisertib and docetaxel may work better in treating patients with squamous cell lung cancer compared to standard chemotherapy.